Titre :

Impact of prior jak-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the cmwp of ebmt

Auteur(s) :

Krger, Nicolaus [Auteur]
Sbianchi, Giulia [Auteur]
Sirait, Tiarlan [Auteur]
Wolschke, Christine [Auteur]
Beelen, Dietrich W. [Auteur]
Passweg, Jakob R. [Auteur]
Robin, Marie [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Vrhovac, Radovan [Auteur]
Helbig, Grzegorz [Auteur]
Sockel, Katja [Auteur]
Conneally, Eibhlin [Auteur]
Rubio, Marie-Thérèse [Auteur]
Centre Hospitalier Universitaire de Nancy [CHU Nancy]
Beguin, Yves [Auteur]
Finke, Jurgen [Auteur]
Bernasconi, Paolo [Auteur]
Morozova, Elena [Auteur]
Clausen, Johannes [Auteur]
Von Dem Borne, Peter A. [Auteur]
Schaap, Nicolaas [Auteur]
Schroyens, Wilfried [Auteur]
Patriarca, Francesca [Auteur]
Di Renzo, Nicola [Auteur]
Yegin, Zeynep Arzu [Auteur]
Hayden, Patrick J. [Auteur]
Mclornan, Donal P. [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Titre de la revue :

Leukemia

Nom court de la revue :

Leukemia

Date de publication :

2021-05-22

ISSN :

1476-5551

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) remains to be determined. We ...
Lire la suite >JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) remains to be determined. We evaluated the impact of RUX on outcome in 551 myelofibrosis patients who received HSCT without (n = 274) or with (n = 277) RUX pretreatment. The overall leukocyte engraftment on day 45 was 92% and significantly higher in RUX responsive patients than those who had no or lost response to RUX (94% vs. 85%, p = 0.05). The 1-year non-relapse mortality was 22% without significant difference between the arms. In a multivariate analysis (MVA) RUX pretreated patients with ongoing spleen response at transplant had a significantly lower risk of relapse (8.1% vs. 19.1%; p = 0.04)] and better 2-year event-free survival (68.9% vs. 53.7%; p = 0.02) in comparison to patients without RUX pretreatment. For overall survival the only significant factors were age > 58 years (p = 0.03) and HLA mismatch donor (p = 0.001). RUX prior to HSCT did not negatively impact outcome after transplantation and patients with ongoing spleen response at time of transplantation had best outcome.Lire moins >

Langue :

Anglais

Comité de lecture :

Oui

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2021-07-06T12:44:18Z
2024-03-04T14:22:19Z